NSCLC (Issue 7)

Oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals involved in the treatment of patients with lung cancer will gather July 2015, at the Hyatt Regency in Huntington Beach, California, for the 16th Annual International Lung Cancer (ILC) Conference.

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.

Two presentations at this year’s American Association for Cancer Research (AACR) annual meeting linked a specific microRNA (miRNA), miR-34a, to an active area in immunotherapy, programed cell death-1 (PD-1) protein and its ligand, PD-L1.

This Q&A with Benjamin P. Levy, MD discusses the treatment of patients with NSCLC who have EGFR exon 19 deletions.

The US Food and Drug Administration (FDA) released new guidance on the use of alternative endpoints, in addition to overall survival (OS), for clinical trials of non–small cell lung cancer (NSCLC) therapies.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses combining bevacizumab with EGFR tyrosine kinase inhibitors (TKI) in the treatment of lung cancer.

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.

Leaders of Roswell Park Cancer Institute (RPCI) in Buffalo, New York, have agreed to collaborate with the Center for Molecular Immunology (CIM) in Cuba to evaluate a therapeutic anticancer vaccine for non–small cell lung cancer (NSCLC) in the United States.